IL-6 Signaling in Psoriasis Prevents Immune Suppression by Regulatory T Cells

Wendy A. Goodman, Alan D. Levine, Jessica V. Massari, Hideaki Sugiyama, Thomas S. McCormick and Kevin D. Cooper

*J Immunol 2009; 183:3170-3176; Prepublished online 31 July 2009; doi: 10.4049/jimmunol.0803721
http://www.jimmunol.org/content/183/5/3170

Why The JI?

- **Rapid Reviews! 30 days** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Speedy Publication!** 4 weeks from acceptance to publication

References This article cites 38 articles, 16 of which you can access for free at:
http://www.jimmunol.org/content/183/5/3170.full#ref-list-1

Subscription Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

Permissions Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
IL-6 Signaling in Psoriasis Prevents Immune Suppression by Regulatory T Cells

Wendy A. Goodman, Alan D. Levine, Jessica V. Massari, Hideaki Sugiyama, Thomas S. McCormick, and Kevin D. Cooper

T memory/effector cells (Tmem/eff) isolated from psoriatic patients are chronically activated and poorly suppressed by regulatory T cells (Treg). The proinflammatory cytokine IL-6, which signals through Stat3, allows escape of Tmem/eff cells from Treg-mediated suppression in a murine system. We show here that IL-6 protein is markedly elevated and most highly expressed by CD31+ endothelial cells and CD11c+ dermal dendritic cells (DCs) in lesional psoriatic skin. We hypothesized that exposure to high IL-6 in lesional tissue may lead to the dampened Treg function observed in psoriasis patients. Indeed, we found that IL-6, but not other Stat3-activating cytokines, was necessary and sufficient to reverse human T cell suppression by Treg in an in vitro model using activated DCs as a source of IL-6. IL-6Rα and gp130 expression was significantly elevated in psoriatic effector T cells compared with normal controls. Overall, IL-6Rα expression on Treg exceeded that of effector T cells, and both populations phosphorylated Stat3 in response to IL-6. Phosphorylation of Stat3 in T cells contributes to Th17 differentiation and we identify cells within lesional tissue that coexpress CD3, IL-17, and IL-6, indicating that Th17 cells are present in vivo within the psoriatic Tmem/eff population and contribute to IL-6-mediated resistance to Treg suppression. Taken together, T lymphocytes trafficking into lesional psoriatic skin encounter high IL-6 from endothelial cells, DCs, and Th17 cells, enabling cutaneous T cell escape from Treg suppression and Th17 participation in inflammation. Targeting IL-6 signaling pathways in psoriasis may rebalance Treg/T effector activity and ameliorate disease. The Journal of Immunology, 2009, 183: 3170–3176.

Psoriasis is a prevalent, chronic inflammatory disease of the skin mediated by cross-talk between epidermal keratinocytes, dermal vascular cells, and immune cells including activated APCs and CD2+CD45RO+ T memory/effector cells (Tmem/eff)1 (1–3). Increased proliferation of keratinocytes in conjunction with inflammation leads to epidermal hyperplasia, characteristic of lesional psoriatic skin. The central, pathogenic role of activated T cells in the development of psoriatic lesions has been demonstrated by the clinical efficacy of drugs that inhibit T cell activation or deplete activated Tmem/eff from psoriatic skin (4–7).

Under conditions of healthy immune homeostasis, the activation of Tmem/eff is controlled by CD4+Foxp3+CD25high, naturally occurring regulatory T cells (Treg), which are indispensable for the maintenance of self-tolerance (8). Depletion of Treg, both in mice and in humans, results in severe autoimmune disease (9) for which there is no compensatory mechanism. The frequency and/or function of Treg is compromised in a number of human autoimmune diseases (reviewed in Ref. 9), and we previously demonstrated that Treg isolated from psoriatic patients are less capable than those from normal donors of suppressing the proliferation of responder T cells from normal and psoriatic donors (10).

Lymphocyte infiltration into superficial perivascular skin is an early critical cellular event in psoriasis. Once in the lesional psoriatic skin, both Th1 and Th17 Tmem/eff are activated by endogenous APCs and produce proinflammatory cytokines and chemokines (11, 12). In turn, these cytokines, particularly in the presence of fibronectin, lead to cell cycle entry of psoriatic keratinocyte stem cells (1), indicating that keratinocytes in the abnormal milieu of psoriatic uninvolved skin are “primed” to respond to T cells (13). Within an altered skin microenvironment rich in EDA-fibronectin (14), dendritic cell (DC)-T cell-keratinocyte cross signaling is thought to lead to epidermal expansion and clinical plaques.

In the present study, we investigated mechanism(s) responsible for the loss of human Treg-mediated suppression of Tmem/eff previously reported in psoriasis and other autoimmune disorders (9, 10). In mice, the proinflammatory cytokine IL-6 was shown to render effector T cells (Teff) refractive to suppression (15). Because IL-6 was previously shown to be associated with pathways active in psoriasis (16, 17), we hypothesized that increased IL-6 protein in psoriatic skin may play a role in dampening Treg function, thus allowing chronic T cell expansion. Indeed, our results indicate that upon entering lesional skin, T effector high levels of IL-6 from endothelial cells, DCs, and Th17 cells. IL-6 exposure leads to diminished Treg cell activity, suggesting that T cells trafficking into psoriatic lesions are modulated by IL-6 to favor activation over suppression. Although the observed loss of functional Treg suppression may be due to IL-6 acting on Teff, Treg, or APC subsets in lesional skin, Stat3 phosphorylation (pStat3) is observed within both T cell subsets and likely contributes to functional alterations in both populations.

Abbreviations used in this paper: Tmem/eff, T memory effector cell; Treg, regulatory T cell; DC, dendritic cell; rh, recombinant human; sIL-6R, soluble IL-6R; MFI, mean fluorescence intensity; DCCM, DC-conditioned medium.

1 Department of Dermatology, ‡Department of Pathology, and †Department of Medicine, Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, OH 44106; †Department of Dermatology, University of Yamanashi, Chuo, Japan; and †Department of Dermatology, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, OH 44106

Received for publication November 6, 2008. Accepted for publication June 29, 2009.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

This work was funded by National Institutes of Health Grants AR051498, P30AR39750, and P01AR50508 (to K.D.C.), the Morphology, Flow Cytometry, and Confocal Microscopy core facilities of the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Center and the Case Comprehensive Cancer Center (Grant P30CA43703), and the Murdough Family Center for Psoriasis.

Address correspondence and reprint requests to Dr. Wendy A. Goodman, Department of Dermatology, University Hospitals Case Medical Center and Case Western Reserve University, 10900 Euclid Avenue, BRB 409A, Cleveland, OH, 44106-4952. E-mail address: wag@case.edu

Abbreviations used in this paper: Tmem/eff, T memory effector cell; Treg, regulatory T cell; DC, dendritic cell; rh, recombinant human; sIL-6R, soluble IL-6R; MFI, mean fluorescence intensity; DCCM, DC-conditioned medium.
Materials and Methods

Isolation and culture of human dermal cells and PBMCs

All studies involving human subjects were approved by the Institutional Review Boards of Case Western Reserve University, University Hospitals Case Medical Center, and the Veterans Affairs Medical Center. Punch biopsies and/or peripheral blood samples were obtained from healthy adult volunteers or patients with moderate plaque psoriasis following informed consent. Primary dermal cells were isolated as previously described (18) and cultured in complete medium (RPMI 1640 containing 10% FBS (Cambrex), t-glutamine, penicillin, streptomycin (all from Cellgro), and 2-ME). PBMCs were prepared from peripheral blood as previously described (10) and adhered to plastic for 1 h to enrich for the nonadherent, lymphocyte-containing fraction. Cell viability was determined by trypan blue exclusion.

Confocal immunofluorescence microscopy

Five-micrometer tissue sections were cut from formalin-fixed, paraffin-embedded blocks. Sections were deparaffinized and rehydrated by sequential 3-min incubations in xylene and ethanol. Ag retrieval was performed to unmask cross-linked epitopes by incubating sections for 20 min in boiling citrate buffer (DakoCytomation) and then cooling them to room temperature. Tissue was labeled overnight at 4°C with goat anti-huIL-6 or goat anti-huIL-17 (both R&D Systems), and mouse anti-huCD45, mouse anti-huCD3, mouse anti-huCD11c, mouse anti-huMac387, mouse anti-huCD31 (all from Abcam), mouse anti-hu-IL-6 (R&D Systems), or appropriate isotype controls. Alexa Fluor 488- or 594-conjugated anti-goat- or anti-mouse secondary Abs (Invitrogen) were used to detect primary Abs and Draq-5 (Axxora) was used as a nuclear marker. Confocal images were acquired using a Zeiss LSM 510 scanning confocal microscope with a ×40 oil immersion Plan-Neofluar objective and a 1.3 numerical aperture. MetaMorph (version 7.1) software (Molecular Devices) was used to calculate the pixel density of labeled cells.

Differential and phenotyping of monocyte-derived DCs

CD14+ cells were isolated from PBMCs by negative selection (Stem Cell Technology) and cultured in complete medium supplemented with recombinant human (rh) IL-4 (500 U/ml; Promega) and rhGM-CSF (1000 U/ml; PeproTech) to generate immature DCs. DCs were pulsed for 2 h with 1 μg/ml LPS (Sigma-Aldrich) on day 7 of culture or left untreated. Pulsed cultures were washed thoroughly to remove residual LPS; DCs and conditioned medium were harvested 16 h after the pulse. Conditioned medium was used in T cell functional assays, and DCs were phenotyped with the following mAbs or appropriate isotype controls: anti-CD11c-allophycocyanin, anti-CD14-allophycocyanin, anti-CD11b-Pacific Blue, or anti-CD80-FITC, (all from BD Biosciences). Samples were analyzed using an LSR II flow cytometer (BD Biosciences). Culture supernatants from 2 × 106 DCs or from 2 × 106 dermal cells were assayed for IL-6 and soluble IL-6R (sIL-6R) content by ELISA (Quantikine kit; R&D Systems) according to the manufacturer’s instructions.

Purification of T lymphocyte populations, functional assays, and IL-6R expression

Nonadherent lymphocytes were washed, rested overnight to decrease transient expression of CD25 on activated T cells, and labeled with anti-CD4-allophycocyanin (Invitrogen) and anti-CD25-PE (BD Biosciences). Cells were sorted by high-speed flow cytometry using a FACSAria (BD Biosciences). CD4+CD25+ T cells were gated using an isotype control Ab and CD4+CD25+ cells were defined as the top 1.5% of CD4+ cells expressing cells within the CD4+ gate (19). Two × 106 CD25+ T cells were cultured with 1 × 104 autologous APCs in 96-well, round-bottom plates. APCs were prepared from total PBMCs by 1-h plastic adherence (to deplete T cells) and the adherent fraction was irradiated with 3000 rad immediately before use in the coculture. Some cocultures were stimulated using microbeads coated with 10 μg/ml anti-CD2/anti-CD3/anti-CD28 (from Miltenyi Biotec) at a 1:4 bead:T cell ratio. When used, CD25+ Treg were added at 1:1 or 1:4 ratios with CD25+ T cells. Where indicated in Results, either rhIL-6 (1–50 ng/ml) or rhIL-23 (1–100 ng/ml) (both from R&D Systems) were added to the cocultures. Cultures containing rhIL-6 also contained 25 ng/ml sIL-6R (R&D Systems). Some assays were cultured in DC-conditioned medium (DCCM; used undiluted) rather than complete RPMI 1640. All cocultures were pulsed with 1 μCi/well [3H]thymidine for the final 16 h of a 7-day culture and harvested using a PhD cell harvester (Cambridge Technology). Proliferation was determined using a Beckman Coulter LS 6000SC scintillation counter. For phenotypic experiments, nonadherent PBMCs were incubated with the following mAbs (or appropriate isotype controls): anti-CD4-Pacific Blue (eBioscience), anti-CD25-allophycocyanin (BD Biosciences), and either anti-IL-6Ra-PE or anti-gp130-PE (both from BD Biosciences). Mean fluorescence intensity (MFI) of the PE channel was calculated for cells within the CD4+CD25+ T lymphocyte gate and the CD4+CD25bright Treg lymphocyte gate. Change in MFI was calculated by subtracting the MFI of isotype-stained samples from the MFI of Ab-labeled samples.

Immunoblots

Cells were stimulated with rhIL-6 (10 ng/ml) and sIL-6R (25 ng/ml) and immunoblotted as previously described (20) with polyclonal Abs specific for p-Y705-Stat3, total Stat3, or β-actin (all from Cell Signaling Technology), then with goat anti-rabbit HRP (Santa Cruz Biotechnology). Chemiluminescent signals were detected using Kodak BioMax MR film.

Statistical analysis

Statistical analysis was performed using either a two-tailed Student’s paired t test or a two-tailed Wilcoxon rank sum test where indicated. For both tests, values of p ≤ 0.05 were considered significant.

Results

Dermal cells from lesional psoriatic skin, but not nonlesional or normal (healthy) skin, release high levels of IL-6 protein spontaneously in culture

Dermal cell suspensions were prepared from punch biopsy material obtained from lesional and nonlesional psoriatic skin or normal (healthy) skin and cultured for 48 h. Conditioned medium was collected at 0, 12, 24, and 48 h after culture and analyzed for released IL-6 by ELISA. Baseline samples (0 h) were collected immediately following cell culture, and no IL-6 was detected in the medium at this time point (Fig. 1A). Following culture for 48 h, the mean level of spontaneous IL-6 released into the supernatants by lesional psoriasis samples was 2507 ± 263 pg/ml (n = 3), significantly higher than the level of IL-6 secreted by nonlesional psoriasis samples (144.5 ± 83 pg/ml, p = 0.008, n = 3) and normal samples (13 ± 5 pg/ml, p = 0.011, n = 3).

Lesional psoriatic skin contains high levels of IL-6bright cells

Normal and psoriatic human skin sections were analyzed for IL-6 expression by immunofluorescence confocal microscopy. IL-6 expression per dermal cell was most intense in lesional psoriatic tissue compared with nonlesional or normal skin (Fig. 1B, p < 0.006, n = 15 fields analyzed in each of 10 patients). Although some IL-6bright cells were also detected in nonlesional psoriatic tissue and normal skin, their frequency (as well as the frequency of total dermal cells) was lower than in lesional psoriatic skin (Fig. 1C, p ≤ 0.02, n = 15 fields analyzed in each of 10 psoriasis patients and 7 normal controls).

IL-6 within the lesional psoriatic dermis localizes to CD45+ leukocytes and CD45− perivascular cells

Most IL-6bright cells in lesional psoriatic skin localized to the papillary tip regions and superficial horizontal vascular plexus (Fig. 2A). Epidermal keratinocytes also produced IL-6 in situ at moderately high levels in lesional and nonlesional psoriatic skin (Fig. 2B, p < 0.006, n = 15 fields analyzed in each of 10 patients). Although some IL-6bright cells were also detected in nonlesional psoriatic skin, their frequency (as well as the frequency of total dermal cells) was lower than in lesional psoriatic skin (Fig. 2C).

To determine the derivation of the IL-6-producing cells, tissue sections were labeled with Abs specific to CD45 and IL-6 (Fig. 2, D–G). CD45+ cells are present in low frequency in both normal (Fig. 2D) and nonlesional psoriatic (Fig. 2E) skin, where they localize primarily to the papillary dermis. Lesional psoriatic skin (Fig. 2, F and G) shows significantly elevated numbers of CD45+ cells, including elongated cells which line the dermal-epidermal junction (Fig. 2F) and organized cellular infiltrates throughout the horizontal plexus (Fig. 2G). The majority of CD45+ cells in normal and psoriatic skin colocalize with IL-6 (white arrows, Fig. 2),...
IL-6 is overexpressed in lesional psoriatic skin. Dermal single-cell suspensions were prepared from nonlesional and lesional psoriatic skin and normal skin. Cells were cultured for 48 h and IL-6 released to the culture medium was determined by ELISA at the indicated times. *p ≤ 0.05, n = 3. B and C, Tissue sections from the indicated sources were labeled with anti-IL-6 Ab or isotype control. B, Intensity of IL-6 within IL-6+ cells was calculated using MetaMorph (version 7.1) imaging software and is expressed as raw pixel density (n = 15 fields per tissue source ± SEM). C, Frequency of dermal cells expressing IL-6 (per mm²) was calculated (n = 15 fields per tissue source ± SEM).

although some IL-6+ cells do not express CD45 (yellow arrows, Fig. 2).

**IL-6 is produced in highest amounts by DCs and endothelial cells in lesional psoriatic skin**

To determine the identity of the IL-6-producing CD45+ and CD45− cells, immunofluorescence staining was performed with Abs specific to CD11c, CD3, Mac387, and CD31. Average IL-6 pixel density for labeled cells was calculated and normalized to the average IL-6 pixel density of keratinocytes from the same sections, generating the fold change in IL-6 intensity for each cell population compared with that of keratinocytes (Table I). This approach allowed us to normalize for varying levels of IL-6 intensity between tissue samples. Among CD45+ leukocytic cells, CD11c+ DCs are the highest producers of IL-6 (1.98 ± 0.4-fold higher than keratinocytes; Table I). These IL-6bright cells are present throughout the papillary dermis and lining the dermal-epidermal junction (Fig. 3A). CD3+ lymphocytes are numerous within psoriatic skin and produce moderate levels of IL-6 (Fig. 3B and Table I), whereas dermal Mac387+ macrophages, found throughout the papillary dermis, produce somewhat less IL-6 (Fig. 3C and Table I). CD31+ endothelial cells, located throughout the papillary tips and horizontal plexus, are uniformly IL-6bright (Fig. 3D), expressing 1.87 ± 0.23-fold higher levels of IL-6 than keratinocytes (Table I).

**IL-17-producing cells are present in lesional psoriatic skin and coexpress CD3 and IL-6**

Because many CD3+ lymphocytes in lesional psoriatic skin expressed IL-6 (Fig. 3B) and IL-6 can be a product of pathogenic Th17 cells (21), we determined the microanatomic location of psoriatic Th17 cells and whether they represent a T cell source of IL-6. Numerous IL-17-expressing cells were found throughout the psoriatic papillary dermis (green and white arrows, Fig. 4) and many coexpressed CD3 (white arrows, Fig. 4A), indicating a Th17 phenotype. IL-6-expressing cells (yellow arrows, Fig. 4B) occupy the same microanatomic niche as IL-17-expressing cells, with many double-labeled IL-17+IL-6+ cells present (white arrows, Fig. 4B).

**IL-6 reverses the suppressive function of human Treg**

We hypothesized that localized, lesional production of IL-6 may modify human Treg function in psoriasis patients. To model the

### Table I. CD11c+ dermal DCs and CD31+ endothelial cells express the highest levels of IL-6 in lesional psoriatic skin

<table>
<thead>
<tr>
<th>Indicated Cells</th>
<th>Density within Normal DCs</th>
<th>Density within Standard DCs</th>
<th>p</th>
<th>Increase over Standard DCs</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD11c+</td>
<td>966.5 ± 30.3</td>
<td>587.1 ± 30.6</td>
<td>0.039</td>
<td>1.98 ± 0.37</td>
</tr>
<tr>
<td>CD3+</td>
<td>914.1 ± 35.7</td>
<td>676.2 ± 21.3</td>
<td>0.0044</td>
<td>1.38 ± 0.09</td>
</tr>
<tr>
<td>Mac387+</td>
<td>1014.0 ± 38.4</td>
<td>958.9 ± 28.7</td>
<td>0.4056</td>
<td>1.08 ± 0.06</td>
</tr>
<tr>
<td>CD31+</td>
<td>1495.2 ± 81.2</td>
<td>832.3 ± 36.3</td>
<td>0.0015</td>
<td>1.87 ± 0.23</td>
</tr>
</tbody>
</table>

*p = 0.05, n = 9 fields (three fields each among three lesional psoriatic samples). 
*p = 0.06, n = 9 fields (three fields each among three lesional psoriatic samples).
CD31+ endothelial cells, represent major sources of IL-6 in lesional psoriatic skin. Double-labeled immunofluorescence shows infiltration of CD11c+ DCs (A), CD3+ T lymphocytes (B), Mac387+ macrophages (C), and CD31+ endothelial cells (D) in lesional psoriasis skin. IL-6-positive cells (yellow arrows), cells positive for the indicated surface marker (green arrows), and colocalized cells (white arrows) are shown. Images are representative of three separate experiments. Scale bar, 50 μm.

FIGURE 3. Immune cell subsets including DCs, as well as CD31+ endothelial cells, represent major sources of IL-6 in lesional psoriatic skin. Double-labeled immunofluorescence shows infiltration of CD11c+ DCs, CD3+ T lymphocytes, Mac387+ macrophages, and CD31+ endothelial cells in lesional psoriasis skin. IL-6-positive cells are shown in yellow, cells positive for the indicated surface marker are shown in green, and colocalized cells are shown in white. Images are representative of three separate experiments. Scale bar, 50 μm.

To functionally assess Treg suppression in the presence of DCCM-derived IL-6, flow cytometry-purified responder T cells (CD4+CD25+) and Treg (CD4+CD25high) were cocultured along with irradiated, allogeneic APCs in MLRs and assayed for T cell proliferation by [3H]thymidine incorporation in the presence or absence of DCCM. Treg-mediated suppression of Teff proliferation was reversed upon culture in LPS-pulsed DCCM (31% suppression) compared with non-LPS-pulsed DCCM (75% suppression; Fig. 5A). Responder T cells cultured in non-LPS-pulsed DCCM and those cultured in LPS-pulsed DCCM proliferated to a similar extent in the absence of Treg (Fig. 5A). To determine whether IL-6 in the DCCM was responsible for the reversal of Treg suppression, responder T cells were cocultured with Treg in LPS-pulsed DCCM in the presence of anti-IL-6-neutralizing Ab. In each of three experiments, the addition of anti-IL-6 restored Treg-mediated suppression, either at 20 or 50 ng/ml (Fig. 5B). Use of an isotype control Ab in place of anti-IL-6 did not restore suppression (data not shown). Proliferation of responder T cells was unaffected by the addition of anti-IL-6 in both fresh medium and DCCM (Fig. 5C).

To determine whether IL-6 alone is sufficient to mediate the loss of Treg suppressive capacity, we added rhIL-6 directly to T cell cocultures. Treg did not proliferate, either in the presence or absence of IL-6 (Fig. 5D) or in the presence of anti-IL-6-neutralizing Ab (data not shown). The proliferation of both normal and psoriatic responder T cells was suppressed by the addition of normal Treg in the absence of IL-6 (60 and 80%, respectively, Fig. 5D). The addition of rhIL-6 to normal and psoriatic Teff/Treg cocultures led to a concentration-dependent reversal of Treg function, with a significant loss of Treg suppression observed at both 10 and 50 ng/ml IL-6, concentrations similar to those present in DCCM (p < 0.01 at both concentrations compared with cocultures without IL-6; n = 3). In contrast to allogeneic APC stimulation, IL-6 did not reverse Treg function when cells were stimulated using anti-CD2/anti-CD3/anti-CD28 microbeads in an APC-free system (Fig. 5E; n = 4).

IL-6 signaling leads to Stat3 phosphorylation, an event that also occurs in response to IL-23 signaling through the IL-23R (22). In contrast to IL-6/IL-6R ligation, normal Treg function in cocultures stimulated with allo-APCs remained intact at rhIL-23 concentrations as high as 100 ng/ml (Fig. 5F; n = 3).
or not with LPS.

A

B

C

D

E

F

expressed significantly elevated IL-6Rα compared with Teff (Fig. 6A, p < 0.01 for normal cells, n = 9; p < 0.02 for psoriasis cells, n = 9). Indeed, when IL-6Rα expression was analyzed on the

FIGURE 6. Effector and Treg from normal and psoriatic patients express IL-6Rα and respond to IL-6 stimulation. A and B, Nonadherent lymphocytes isolated from PBMCs were stained with mAbs specific for CD4, CD25, IL-6Rα, gp130, or appropriate isotype controls. Cells were electronically gated on CD4+ CD25+ or CD4+ CD25high and then analyzed for surface expression of IL-6Rα or gp130. Intensity of IL-6Rα and gp130 expression is expressed as the ΔMFI (MFI of stained samples minus MFI of isotype control samples) (n = 9). Median values are shown by horizontal bars and Wilcoxon rank sum tests were performed with p < 0.05 considered significant. C, Normal and psoriatic CD4+ CD25+ T cells and CD4+ CD25high Treg were isolated from peripheral blood and incubated with or without 10 ng/ml rhIL-6 and 25 ng/ml sIL-6R (to maximize response). Protein lysates were probed with Abs specific for p-Y705 (activated) Stat3, total Stat3, and β-actin. The Western blot shown is a representative experiment from among five individual experiments. N.S., Not significant.

Discussion

Our evidence that human Teff regulation by Treg can be impaired by IL-6 signaling is in agreement with recent work done in mice (15). In this study, we demonstrate high levels of IL-6 in endothelial cells, DCs, macrophages, and IL-17-producing T cells in lesional psoriatic skin. Together with our previous findings of dysfunctional Treg in psoriasis and hyperactivated Treg that are resistant to normal regulation by Treg (10), we now propose that imbalanced Treg/Teff dynamics in psoriasis are mediated by IL-6 signaling events in the lesional skin, acting on T cell subsets which express the IL-6R and which respond functionally through phosphorylation of the transcription factor Stat3.

IL-6 is elevated in psoriasis at both the mRNA (16) and protein (17) levels, and its pleiotropic effects include stimulation of epidermal keratinocyte hyperplasia as well as promoting the differentiation of IL-17-producing T lymphocytes, while inhibiting Treg differentiation (24). We show here that the high levels of IL-6 present within lesional psoriatic skin are derived largely from two populations of cells in intimate contact with T cells migrating into
In addition to promoting a signaling environment in which normal Treg control mechanisms are ineffective, IL-6 contributes directly to the differentiation of pathogenic Th17 cells (32), which are associated with initiation of autoimmunity and inflammation (33). The polarization of naive human T cells to a Th17 phenotype requires Stat3 activation (32), and Stat3 phosphorylation has been demonstrated in both human psoriasis and a murine model of disease (25). Other cytokines that signal through pStat3, including IL-21 and IL-23, are also elevated in psoriasis. Th17 cells, recently identified in cell suspensions from lesional psoriatic skin (34), were reduced following clinical improvement (35) and implicated in disease pathogenesis due to the marked clinical effectiveness of anti-IL-12/23p40, which leads to dramatic reductions of IL-23p19 but not IL-12p35 (5).

Our data place Th17 cells in microanatomical proximity to IL-6-producing cells (Fig. 4), where they also express autocrine IL-6 and may thereby contribute to further Th17 differentiation. Our observations in vivo localize Th17 cells to areas of elevated IL-6 in lesional psoriatic skin, where IL-6 is available and may contribute to Th17 differentiation. Previous reports have suggested that Th17 cells are also resistant to Treg-mediated suppression (36), although our in vitro cocultures using IL-6 did not result in an up-regulation of IL-17 mRNA or protein (data not shown).

Interestingly, activation of Th17 cells in experimental autoimmune encephalitis is associated with escape of Teff from Treg control (37). Given that IL-6 signaling leads to a loss of Treg function (Fig. 5), IL-6-producing cells in the lesion likely contribute to reactivity of tissue Teff by dampening normal Treg control mechanisms. As a critical factor in the homeostatic balance between Th17 cells and Th17 (38), the high levels of IL-6 generated by DCs and endothelial cells in lesional skin likely tip the balance in favor of pathogenic Th1 and Th17 cells over Treg, further allowing for unrestricted T cell activation. Thus, targeting IL-6 and its downstream signaling pathways within lesional psoriatic skin holds promise in the restoration of functional Treg control over Tmem/eff activation.

Acknowledgments
We thank W. M. Sramkoski and A. Rodriguez for excellent technical support for the flow cytometry experiments and M. Lam for excellent support for confocal experiments.

Disclosures
The authors have no financial conflict of interest.

References
IL-6 INHIBITS HUMAN Treg FUNCTION


